Tarsus Pharmaceuticals, Inc. (TARS)
| Market Cap | 2.57B +47.5% |
| Revenue (ttm) | 535.08M +129.0% |
| Net Income | -48.27M |
| EPS | -1.13 |
| Shares Out | 43.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 971,197 |
| Open | 57.38 |
| Previous Close | 57.69 |
| Day's Range | 57.38 - 59.95 |
| 52-Week Range | 38.51 - 85.25 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 94.56 (+58.0%) |
| Earnings Date | Aug 5, 2026 |
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner ... [Read more]
Financial Performance
In 2025, Tarsus Pharmaceuticals's revenue was $451.36 million, an increase of 146.71% compared to the previous year's $182.95 million. Losses were -$66.42 million, -42.52% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price target is $94.56, which is an increase of 58.00% from the latest price.
News
Tarsus Pharmaceuticals chief commercial officer Aziz Mottiwala to depart
Tarsus Pharmaceuticals (TARS) announced that Aziz Mottiwala, chief commercial officer, is departing the company to pursue a new opportunity as CEO of a public medical device company. Effective immedia...
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new op...
Tarsus Pharmaceuticals Transcript: M&A announcement
The acquisition brings a late-stage ocular antiseptic asset with strong clinical differentiation and a clear regulatory path, targeting a large unmet need in retinal procedures. The deal leverages existing commercial strengths, offers significant market potential, and preserves financial flexibility.
Tarsus Pharmaceuticals Press release: M&A announcement
Tarsus Pharmaceuticals issued a press release on July 8, 2026, disclosing material business information to investors.
Tarsus Pharmaceuticals Slides: M&A announcement
Tarsus Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 8, 2026.
Tarsus Pharmaceuticals acquires iRenix Medical
Tarsus Pharmaceuticals (TARS) announced the acquisition of iRenix Medical. Upfront consideration is approximately $75M, consisting of $37.5M in cash and $37.5M in Tarsus common stock. Potential approv...
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care
Tarsus Pharmaceuticals Slides: Corporate presentation
Tarsus Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 8, 2026.
Culper Research announces Tarsus Pharmaceuticals short position
Culper Research said on X: “NEW: We are short Tarsus Pharmaceuticals (TARS) $TARS, maker of XDEMVY, a $2,000 eyedrop for demodex blepharitis. We think XDEMVY rests on a TARS-funded Medicare…
Tarsus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
XDEMVY has achieved rapid adoption and strong revenue growth, with peak sales guidance raised to over $2 billion due to expanded prescriber base and effective DTC campaigns. The company is advancing its pipeline in ocular rosacea and Lyme disease, while maintaining a robust commercial infrastructure and monitoring profitability opportunities.
Tarsus Pharmaceuticals Transcript: 46th Annual William Blair Growth Stock Conference
XDEMVY continues strong commercial growth with expanded DTC campaigns and robust reimbursement, while new key account leaders and clinical studies drive deeper market penetration. Pipeline programs for ocular rosacea and Lyme disease are advancing, with pivotal data expected in 2027.
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Pharmaceuticals Transcript: Stifel 2026 Virtual Ophthalmology Forum
XDEMVY has achieved strong adoption with over 20,000 prescribers and 500,000 patients treated, driving a raised peak sales outlook to $2 billion. Pipeline programs in ocular rosacea and Lyme disease prevention are advancing, with robust reimbursement and a solid cash position supporting continued growth.
Tarsus Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
XDEMVY has driven strong revenue growth and broad prescriber adoption, supported by effective DTC campaigns and a robust sales strategy. Pipeline programs in ocular rosacea and Lyme disease offer significant future potential, while international expansion is being evaluated amid policy considerations.
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but of...
Tarsus Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
XDEMVY’s commercial momentum continues with strong Q1 results, expanding prescriber base, and improved DTC ROI. Pipeline assets in ocular rosacea and Lyme disease advance, with strategic focus on operating leverage and payer value. Guidance and market opportunity remain robust.
Tarsus Pharmaceuticals reports Q1 EPS (16c), consensus (40c)
Reports Q1 revenue $162.05M, consensus $148.73M. “XDEMVY is driving a fundamental shift in how Demodex blepharitis is diagnosed and treated,” said Bobak Azamian, Chief Executive Officer and Chairman o...
Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw XDEMVY net product sales rise over 85% year-over-year to $145 million, with strong physician adoption and expanding retreatment rates. Full-year guidance of $670–$700 million in sales was reaffirmed, and pipeline programs for Lyme disease and ocular rosacea advanced on schedule.
Tarsus Pharmaceuticals Earnings release: Q1 2026
Tarsus Pharmaceuticals released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Tarsus Pharmaceuticals Quarterly report: Q1 2026
Tarsus Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 6, 2026.
Tarsus Pharmaceuticals Slides: Q1 2026
Tarsus Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product s...
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m.
Tarsus Pharmaceuticals Proxy statement: Proxy filing
Tarsus Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Tarsus Pharmaceuticals Proxy statement: Proxy filing
Tarsus Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.